3M

3M is one of the most contentious large-cap stories in US industrials. The legacy investor pitch — a 65-year dividend aristocrat with diversified exposure to global manufacturing — was shattered between 2018 and 2024 by two existential litigations: the combat-arms earplug class action (eventually settled for $6 billion) and the PFAS «forever chemicals» mass-tort exposure (settled for $10.3 billion in 2023). On top of this, 3M spun off its healthcare business as Solventum (SOLV) in April 2024 to clean up the structure. The 2026 story is what comes next. The new 3M is a leaner, capital-light industrials platform with three segments: Safety & Industrial, Transportation & Electronics, and Consumer. Management under new CEO William Brown has guided FY2026 organic sales growth of 1 to 3 percent — modest but the first positive print in three years — with operating margins expanding 100 basis points to roughly 22 percent. The dividend was reset lower (from $6 to $4.40 annualised) after Solventum, but the lower base is now genuinely covered by free cash flow at 65% payout. Free cash flow guided to $5 to 5.5 billion for 2026, against a market cap of $80 billion — a free-cash-flow yield above 6%.

3M is a classic deep-value/special-situation name on smart-money tracker. Pershing Square does not hold it (Ackman exited industrials), but Trian Partners and Glenview Capital re-entered through 2025 as the litigation overhang lifted. The activist case rests on operational simplification: 3M still operates roughly 60 manufacturing sites worldwide with a long tail of low-margin product lines that management is exiting. Smart-money buyers like the setup because the litigation tail is now fully reserved (PFAS settlement payments run through 2036 but are matched by annual operating cash flow), the dividend is sustainable, and the operational story is genuinely incremental. The bear-camp counterparts include Carson Block's Muddy Waters, who flagged ongoing PFAS regulatory risk in early 2025 — a reminder that not all legacy issues are fully priced in.

3M trades at 13.8× forward earnings and 9.7× EV/EBITDA — both meaningful discounts to industrial peers Honeywell (19.5× / 13×) and Illinois Tool Works (24× / 16×). The discount reflects two persistent investor concerns: lingering PFAS uncertainty and the unproven Brown-era operational story. Free-cash-flow yield at 6.2% is one of the highest in S&P industrials. Bull case (Brown delivers 100bps annual margin expansion + buyback compounds, litigation tail behaves): fair value $185. Bear case (PFAS reopens or organic growth stays sub-2%): fair value $115.

1. July 25, 2026: Q2/2026 earnings — first full quarter of new pricing actions in Safety & Industrial; expect commentary on Brown's 100bps margin glidepath.
2. October 22, 2026: Q3/2026 earnings — updated FY guide; potential announcement of further portfolio divestitures.
3. Throughout 2026-2027: PFAS state attorney-general settlement progress — major remaining wildcard; each meaningful state-by-state resolution would tighten investor confidence.

3M is the rare large-cap where the bull case requires nothing exotic — just steady execution from a credible CEO, while the bear case requires a tail event (PFAS reopens) that the market has been worrying about for five years. That is exactly the asymmetric setup that contrarian value investors look for. The catch is patience: the operational turnaround takes 24 to 36 months to fully express in numbers, and during that window the stock can stagnate for quarters at a time. I view this as a barbell name: 2 to 3% of a balanced portfolio, sized to be patient enough to wait for the eventual re-rating without forcing the timing.